You are viewing an incomplete version of our website. Please click to reload the website as full version.

RAS P21 Protein Activator (GTPase Activating Protein) 1 (RASA1) (AA 948-1048) antibody

Details for Product No. ABIN395417, Supplier: Log in to see
Antigen
  • CG9209
  • D-RasGAP
  • Dmel\\CG9209
  • RAS-GAP
  • RasGAP
  • RasGap
  • rasGap
  • CM-AVM
  • CMAVM
  • GAP
  • PKWS
  • RASA
  • RASGAP
  • p120GAP
  • p120RASGAP
  • GAPX
  • Rasa
  • Gap
Epitope
AA 948-1048
20
13
9
8
5
5
4
3
2
2
2
2
1
1
1
Reactivity
Human
93
38
35
1
Host
Mouse
72
20
2
Clonality (Clone)
Monoclonal ()
Conjugate
Un-conjugated
4
4
4
2
2
2
2
2
2
2
2
2
2
2
2
Application
Western Blotting (WB)
67
27
22
14
11
9
8
1
1
1
1
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Showcase your results, aid the scientific community, and receive a full refund.

Contribute a validation

Learn more

Available images

Immunogen RASA1 (NP_002881, 948 a.a. ~ 1048 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 K
Clone 2C12
Isotype IgG1 kappa
Specificity RASA1 (NP_002881, 948 a.a. ~ 1048 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.
Purification This antibody is purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
Alternative Name RASA1 (RASA1 Antibody Abstract)
Background Synonyms: Serine protease inhibitor J6, 47 kDa heat shock protein, Collagen-binding protein, Colligin, Serpin H1,Hsp47, Cbp1, Serpinh1
Molecular Weight 116403 DA
Gene ID 12406
NCBI Accession NP_002881
Research Area Cancer, Cell Cycle, Cell Structure
Pathways
Application Notes Western blot = 1:500-1000
Comment

Background: The protein encoded by this gene is located in the cytoplasm and is part of the GAP1 family of GTPase-activating proteins. The gene product stimulates the GTPase activity of normal RAS p21 but not its oncogenic counterpart. Acting as a suppressor of RAS function, the protein enhances the weak intrinsic GTPase activity of RAS proteins resulting in the inactive GDP-bound form of RAS, thereby allowing control of cellular proliferation and differentiation. Mutations leading to changes in the binding sites of either protein are associated with basal cell carcinomas. Alternative splicing results in two isoforms where the shorter isoform, lacking the N-terminal hydrophobic region but retaining the same activity, appears to be abundantly expressed in placental but not adult tissues.

Restrictions For Research Use only
Buffer PBS with 0.09% (w/v) sodium azide.
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage 4 °C/-20 °C
Storage Comment Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles
Expiry Date 6 months
Supplier Images
Western Blotting (WB) image for anti-RAS P21 Protein Activator (GTPase Activating Protein) 1 (RASA1) (AA 948-1048) antibody (ABIN395417) RASA1 monoclonal antibody (M01), clone 2C12 Western Blot analysis of RASA1 expression...
Immunohistochemistry (IHC) image for anti-RAS P21 Protein Activator (GTPase Activating Protein) 1 (RASA1) (AA 948-1048) antibody (ABIN395417) anti-RAS P21 Protein Activator (GTPase Activating Protein) 1 (RASA1) (AA 948-1048) antibody (Image 2)
Background publications Hemerly, Bastos, Cerutti: "Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas." in: European journal of endocrinology / European Federation of Endocrine Societies, Vol. 163, Issue 5, pp. 747-55, 2010 (PubMed).

Wiemels, Kang, Chang et al.: "Backtracking RAS mutations in high hyperdiploid childhood acute lymphoblastic leukemia." in: Blood cells, molecules & diseases, Vol. 45, Issue 3, pp. 186-91, 2010 (PubMed).

Anand, Majeti, Acevedo et al.: "MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis." in: Nature medicine, Vol. 16, Issue 8, pp. 909-14, 2010 (PubMed).

Bachas, Schuurhuis, Hollink et al.: "High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine." in: Blood, Vol. 116, Issue 15, pp. 2752-8, 2010 (PubMed).

Thiex, Mulliken, Revencu et al.: "A novel association between RASA1 mutations and spinal arteriovenous anomalies." in: AJNR. American journal of neuroradiology, Vol. 31, Issue 4, pp. 775-9, 2010 (PubMed).